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Reactivation of p53 by release of the functional
protein from its inhibition by MDM2 provides an effi-
cient, nongenotoxic approach to a wide variety of
cancers. We present the cocrystal structures of two
complexes of MDM2 with inhibitors based on 6-
chloroindole scaffolds. Both molecules bound to a
distinct conformational state of MDM2 with nM-mM
affinities. In contrast to other structurally character-
ized antagonists, which mimic three amino acids of
p53 (Phe19, Trp23, and Leu26), the compounds
induced an additional hydrophobic pocket on the
MDM2 surface and unveiled a four-point binding
mode. The enlarged interaction interface of the inhib-
itors resulted in extension of small molecules binding
toward the ‘‘lid’’ segment of MDM2 (residues 19–
23)—a nascent element that interferes with p53 bind-
ing. As supported by protein engineering and molec-
ular dynamics studies, employing these unstable
elements of MDM2 provides an efficient and yet un-
explored alternative in development of MDM2-p53
association inhibitors.
INTRODUCTION
Tumor development requires breaching the line of defense
formed by the ‘‘guardian of the genome,’’ the tumor suppressor
p53 protein (Brown et al., 2009; Cheok, et al., 2011). About 50%
of all human cancers inactivate p53 by mutations, and in the re-
maining the wild-type (WT)-p53 activity is most commonly
repressed by the MDM2-mediated ubiquitination (Brown et al.,
2009). The release of the functional p53 from its MDM2-medi-
ated regulation provides an efficient, nongenotoxic approach
to cancer therapy. Substantial progress has been made in
discovering p53-activating molecules in recent years (Cheok
et al., 2011; Ding et al., 2013; Vogel et al., 2012; Wade et al.,
2013; Zhao et al., 2013). Three different classes of small-mole-Structure 21, 2143–21cule MDM2 antagonists are currently under clinical investigation
(Wade et al., 2013) and, in addition, p53-stapled peptides have
emerged as a promising modality for the p53-Mdm2 and p53-
Mdmx interactions (Baek et al., 2012; Chang et al., 2013).
Interaction between p53 and MDM2 involves their N-terminal
segments and relies on steric complementarity between the
hydrophobic cleft in the p53-binding domain of MDM2 (resi-
dues 25–110) and the hydrophobic face of an a helix in the
p53 transactivation domain (residues 18–26) (Joerger and
Fersht, 2008; Kussie et al., 1996; Popowicz et al., 2011; Stoll
et al., 2001). Key to this interaction is a triad of p53 amino acids
that insert deeply into the MDM2 cleft: Phe19, Trp23, and
Leu26 (designated as three subpockets on MDM2; Figure 1;
Figure S1 available online). The MDM2-p53 recognition is a dy-
namic and multistage process that employs the binding-
induced folding of p53 (Kussie et al., 1996; Popowicz et al.,
2011; Uesugi and Verdine, 1999; Lee et al., 2000), the rear-
rangement of the Leu26 subpocket of MDM2 by a twist of the
Tyr100 ring from the ‘‘closed’’ to the ‘‘open’’ (anti)conformations
(as defined by Popowicz et al., 2007, 2008; Kussie et al., 1996;
Dastidar et al., 2009; Uhrinova et al., 2005), and the dissociation
of a transient a-helical N-terminal ‘‘lid’’ segment of MDM2 (res-
idues 19–23) from the proximity of the p53-complementary
interface (McCoy et al., 2003; Showalter et al., 2008; Zhan
et al., 2012).
Until now, all structurally characterized low-molecular-weight
inhibitors of the MDM2-p53 interaction targeted the same
‘‘closed’’ Tyr100 state and were incapable of reaching the N-ter-
minal ‘‘lid’’ segment, an intrinsically disordered region of MDM2
(Popowicz et al., 2011; Shangary and Wang, 2009; Do¨mling,
2008; Graves et al., 2012). Here, we present X-ray structures
as evidence of two MDM2 complexes that reveal inhibitor mole-
cules bound to the ‘‘open’’ Tyr100 conformation, leading to a
four-point pharmacophore model for this pharmacologically
important protein-protein interaction.RESULTS AND DISCUSSION
Structure of the MDM2-KK271 Complex
Our approach for protein-protein inhibitor development has been
based on multicomponent reaction chemistry (Do¨mling, 2006,51, December 3, 2013 ª2013 Elsevier Ltd All rights reserved 2143
Figure 1. X-Ray Structure of MDM2-p53 Complex
(PDB ID code 1YCR) Numbering of secondary structure elements follows the
labels used by Kussie et al. (1996). Because the p53-peptide replaces the
N-terminal segment of MDM2, the ‘‘lid’’ helix is dissociated from the surface of
MDM2, unfolds, and is invisible in the electron density.
See also Figure S1.
Structure
Inhibitors of MDM2-p53Do¨mling et al., 2012) (Figure 2) and started with the model that
consisted of three features (Popowicz et al., 2011; Shangary
and Wang, 2009; Do¨mling, 2008; Graves et al., 2012) obtained
by replacing the key p53 residues by general requirements of hy-
drophobicity (for Leu and Phe) and adding a specific ‘‘anchor’’Figure 2. Formulas of Inhibitors and Syntheses of KK271 and YH300
Syntheses of KK271 and YH300 using the one-pot Ugi multicomponent reactions
the Trp23-mimicking substituent is marked in red, and the Leu25-mimicking moi
2144 Structure 21, 2143–2151, December 3, 2013 ª2013 Elsevier Ltdfeature constraining the position of a tryptophan analog during
the search (Koes et al., 2012; Czarna et al., 2010). This three-
point pharmacophore screening yielded compound KK271,
which was found to inhibit the MDM2-p53 interaction with Ki =
1,200 nM (Tables 1 and S1). Crystals of the KK271-MDM2 com-
plex unexpectedly revealed two inhibitor molecules bound to a
single protein chain (Figures 3 and S2; Table 1). The overall
fold of MDM2 in complex with KK271 was similar to the native
MDM2-p53 structure with the main-chain root-mean-square de-
viation (rmsd) of 0.69 A˚. The Trp23 pocket of MDM2 is filled with
the 6-chloroindole-2-hydroxamic acid, similarly to the native
Trp23 of p53, forming extensive hydrophobic interactions with
Val93, Gly58, and Leu54. The central, peptidic core of the com-
pound was solvent exposed and did not directly contact the pro-
tein, providing the possibility for modifications to improve the
drug likeness. Unexpectedly, we found that the isobutyl element
filled the Phe19 pocket, and the benzyl moiety was bound within
the Leu26 pocket in spite of structural resemblance between the
benzyl and isobutyl substituents of KK271 to the p53 amino
acids Phe19 and Leu26, respectively. This represents a mirror
image of the native p53 interaction with the indole moiety as a
pseudoplane of symmetry and is similar to an arrangement pre-
viously described for a spiro-oxindole inhibitor (Popowicz, et al.,
2010). The isobutyl side chain loosely occupied the Phe19
pocket, forming hydrophobic contacts to Ile61, Val93, and. YH119 was synthesized as described in Huang et al. (2012). The anchoring of
ety is marked in blue.
All rights reserved
Table 1. Data Collection and Refinement of Crystallographic
Structures and FP Assay Data
KK271-MDM2 YH300-MDM2
Ki from FP assay (mM) 1.2 0.6
Space group P 65 2 2 P41 212
Cell constant
a 53.52 64.341
b 53.52 64.341
c 122.27 81.685
Resolution range (A˚) 46.35–2.14 50.54–1.91
Observed reflections 63,031 116,285
Unique reflections 11,501 12,100
Whole resolution range
Completeness (%) 97.6 94.7
Rmerge (%) 2.6 3.4
I/s (I) 32.03 26.06
Last resolution shell
Resolution range (A˚) 2.24–2.14 2.0–1.9
Completeness (%) 84.2 97.5
Rmerge (%) 10.0 31.4
I/s (I) 9.8 4.6
Refinement
No. of reflections 10,366 13,246
Resolution (A˚) 18.5–2.14 20–1.9
R factor (%) 18.5 18.02
Rfree (%) 22.1 20.3
Average B (A˚2) 33.3 28.4
Rms bond length (A˚) 0.01 0.01
Rms angles () 1.8 1.5
Content of asymmetric unit
No. of complexes 1 1
No. of protein residues/atoms 85/701 94/774
No. of solvent atoms 105 110
See also Figures S2 and S4.
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Inhibitors of MDM2-p53Gly58. Binding of the benzyl group to the Leu26 pocket was sub-
stantially different from that of the majority of known inhibitors
(Figure S3). Owing to the length and flexibility of the scaffold,
this part of the inhibitor binds close to helix IV of MDM2 (Figures
1, 3, and S2) andwas involved in a parallel aromatic stackingwith
His96, with 3.7 A˚ spacing between the rings. Similar p-stacking
contacts were observed in a spirocyclic indolone, a-aminoacyla-
mide (Popowicz, et al., 2010), and chromenotriazolopyrimidine
(Allen et al., 2009), but not in the structures of an imidazoline, nut-
lin, and benzodiazepinedione (Popowicz, et al., 2011, Vassilev
et al., 2004; Huang et al., 2012).
Although the binding mode of the first inhibitor was similar to
other known antagonists, the presence of the second inhibitor
molecule was a surprise. Strikingly, the benzyl group of the
second inhibitor molecule is deeply inserted inside MDM2
occupying a double-sized Leu26 subpocket enlarged by rear-
rangement of Tyr100 side chain into the ‘‘open’’ conformation
(c1 = 171). Rearrangement of the Tyr100 ring constrainedStructure 21, 2143–21Tyr104 (c1 = 131) in a conformation with its aromatic plane
parallel to the Tyr100 ring plane. The conformational selection
of the additional inhibitor molecule was accomplished by
flipping the Leu54 side chain to the anticonformation
(c1 = 160), maximizing van der Waals contacts with both
small molecules.
Structure of the MDM2-YH300 Complex
To test the hypothesis of a general four-point pharmacophore
model in the MDM2 receptor, we designed small molecules
providing the three-point canonical pharmacophore model and
an additional hydrophobic point extending the Leu26-mimicking
pharmacophore. Based on the two small molecules binding in
the MDM2-KK271 complex, we combined the benzyl group of
the first molecule with the phenyl group of the second molecule
using a short oxymethylene linker. With this design we hoped to
fill the extended Leu26 pocket and to constrain Tyr100 in a posi-
tion beneficial for binding larger inhibitors. In fact this process
yielded, among others, compound YH300 with Ki = 600 nM (Ta-
bles 1 and S1). YH300 is an ‘‘elongated’’ derivative of YH119
(Figure 1) previously described by us to have Ki = 1,800 nM
(Huang et al., 2012). The cocrystal structure of the MDM2-
YH300 complex confirmed that the compound exhibited a
four-point interaction mode (Figures 4 and S4). Despite different
crystal contacts, both protein chains had very similar structures
(with all atom rmsd = 0.07 A˚).
As hypothesized, the large 4-chlorobenzyl phenyl ether was
found to fill the enlarged Leu26 new subpocket. The pocket is
partially formed by the intrinsically disordered N terminus
(MQIPASEQV). Moreover, the group forms an extended network
of van der Waals contacts with Val93, Leu54, His96, and the
Tyr100 in the ‘‘open’’ conformation. The aryl-imidazole p-stack-
ing interaction with His96 is not seen anymore in the X-ray lattice
because of the shift of the midphenyl ring by ca. 2.3 A˚ toward the
center of the pocket. The His96 side chain does, however, keep
electrostatic contacts with the internal aryl group and the meth-
yleneoxy linker fragment. The position of the terminal, 4-chloro-
phenyl ring overlaps with the phenyl ring of the second KK271
molecule. The Phe19 subpocket is occupied by a tert-butyl
group and makes van der Waals contacts with Ile61 and Val93
(analogous to those maintained by KK271).
Molecular Dynamics
The scale of the conformational rearrangements in the protein is
clearly visible after removing the inhibitor from the model (Fig-
ures 3B and S3). The MDM2 cleft reaches far toward helix IV
and is much larger than in other MDM2 complexes. Conse-
quently, the MDM2-KK271 structure represents the most pro-
found example of conformational adaptability of the protein to
large ligands. The c1 angles of His96 and Tyr100 were observed
as indicators of the Leu26 pocket shape (Figures 5, S5, and S6).
Interestingly, only the p53-MDM2 complex maintained a stable
conformation of these residues (Tyr100 c1z120, His96
c1z60) (Figure S6). In the unliganded protein, as well as the
KK271 and nutlin-complexes, the side chains of both residues
were flipping between two metastable positions: ‘‘open’’
(Tyr100 c1z180) and ‘‘closed’’ (Tyr100 c1z60) (Figures 5
and S5). We have also analyzed if the N-terminal fragment of
MDM2 has an influence on the behavior of the pocket by51, December 3, 2013 ª2013 Elsevier Ltd All rights reserved 2145
Figure 3. Crystal Structure of KK271 in
Complex with MDM2
(A) Key residues of MDM2 in proximity of the two
inhibitor molecules are highlighted.
(B) The extended Leu26 pocket is filled with benzyl
rings of two inhibitor molecules.
See also Figures S2 and S3.
Structure
Inhibitors of MDM2-p53performing similar simulations on the complexes with an added
N-terminal region. The result was similar, revealing additional
stabilization of His96 by the N termini (Figure S6) and Tyr100
switching between the ‘‘open’’ and ‘‘closed’’ conformations.
The ease of Tyr100 rotation at room temperature and the fact
that the ‘‘open’’ conformation was populated for a significant
fraction of simulations time, implies that a low-energy barrier of
Tyr100 side chain rotation and low difference in the Gibbs free
energies exist for the ‘‘open’’ and ‘‘closed’’ Tyr100 rotamers.
The previous computational studies performed on MDM2-pep-
tide complexes revealed that both ‘‘open’’ and ‘‘closed’’
Tyr100 states can yield similar binding affinities (Dastidar et al.,
2008).
Molecular dynamics simulations performed on the MDM2-
YH300 complex confirmed that the four-point binding mode of
the inhibitor was preserved and the Tyr100 side chain was stabi-
lized in a single ‘‘open’’ conformation (c1 angle z171) (Fig-
ure 5) simultaneously forming hydrophobic contacts with the
ligand molecule.
NMR Measurements
In theMDM2-YH300 structure, the extended ligand chlorophenyl
ring of the inhibitor was buried in a hydrophobic cleft covered
by the N-terminal ‘‘lid’’ segment of MDM2 (residues 18–24),
and this prompted us to investigate the role of this element in
the small-molecule inhibitor binding. It is assumed that at room
temperature MDM2 exists in two states: with the ‘‘lid’’ bound
(90%) and dissociated (10%) (Showalter et al., 2008), giving
ca. 1.2 kcal/mol free energy of dissociation. In order to dissect
the role of this element in ligands binding, a mutant MDM2
with the helix-breaking amino acids in the middle of the ‘‘lid’’
element was engineered (the Ser22Pro, Glu23Gly double muta-
tion). Structural properties of the mutant protein were assessed
by the 1H-15N-HSQC nuclear magnetic resonance (NMR) spec-2146 Structure 21, 2143–2151, December 3, 2013 ª2013 Elsevier Ltd All rights reservedtroscopy. The spectrum of the mutated
protein turned out to be significantly
different from its wild-type counterpart
and not only local but also long-range
chemical shift perturbations were
observed (Figures 6A and 6B). The two
regions most affected by the mutations
were the ‘‘lid’’ helix itself and a comple-
mentary area proximal to the p53-binding
pocket. We found that the pattern of
chemical shift perturbations induced by
the mutations was in remarkably good
agreement with crystallographic struc-
tures of MDM2 complexes with the ‘‘lid’’
helix defined by electron density (Fig-
ure 6D), proving that despite the dynamiccharacter of the association and crystal lattice packing effects,
the static representation provided by our X-ray structures is
consistent with the ensemble average in solution state. Further-
more, superposition of the MDM2 X-ray structures containing
the ‘‘lid’’ element indicates that it is structurally preserved also
in other MDM2 complexes resolved by X-ray crystallography
(Figure 6C).
ITC Measurements
To quantify the effect of the ‘‘lid’’ helix on binding of p53, we per-
formed isothermal titration calorimetry with the p53 peptide (res-
idues 19–37) and found that the Ser22Pro Glu23Gly mutations in
Mdm2 enhance the affinity of p53 3.3-fold (0.6 kcal/mol differ-
ence in the free energies of binding; Tables 2 and S2). Breaking
of the ‘‘lid’’ also changed the thermodynamic signature of the
interaction by inverting the sign of entropic contribution and
making the association enthalpy driven. These differences in
the thermodynamics of p53 association with the native and
mutant MDM2’s may be intuitively explained by competition of
the p53 transactivation domain with the transiently structured
‘‘lid’’ that unfolds when not bound (Showalter et al., 2008; Zhan
et al., 2012). Finally, we probed the influence of the ‘‘lid’’ element
on binding of small molecules. By using a competitive AIDA-
NMR experiment (Bista et al., 2009; Czarna et al., 2009; Krajew-
ski et al., 2007), we found that both YH300 and nutlin-3 are less
effective in dissociating the mutant-MDM2-p53 complex, owing
to a stronger interaction in comparison to the WT-MDM2-p53
interaction (Table S3).
Conclusions
In conclusion, the X-ray structures of the two small-molecule/
MDM2 complexes show the inhibitor molecules to be bound to
the ‘‘open’’ Tyr100 conformation in a highly extended manner.
By developing a line of inhibitors that disrupt the MDM2-p53
Figure 4. Crystal Structure of YH300 in
Complex with MDM2
(A) Key residues of MDM2 around the inhibitor are
highlighted.
(B) The 4-chlorobenzyl phenyl ether fills the hy-
drophobic cavity formed by an extended L26
pocket and the hydrophobic surface of the N-ter-
minal ‘‘lid’’ helix.
See also Figure S4 and Movie S1.
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Inhibitors of MDM2-p53interaction, we demonstrated that rearrangements of aromatic
side chains around the p53-interaction interface are associated
with only modest energetic penalties (Chen and Luo, 2007; Espi-
noza-Fonseca and Trujillo-Ferrara, 2006; Espinoza-Fonseca and
Garcı´a-Machorro, 2008) and local instabilities in the protein’s
binding pocket might be successfully used for extending
ligand-protein interaction by formation of a deep hydrophobic
pocket formed by back folding of the intrinsically disordered
N-terminal lid region, normally seen unfolded in all other MDM2
structures (Movie S1). Therefore, we propose a four-point
pharmacophore model that should lead to the design of novel
classes of antagonists of theMDM2-p53 interaction and suggest
a new possibility of affinity optimization by preventing ‘‘lid’’
dissociation.EXPERIMENTAL PROCEDURES
Protein Expression, Purification, and Crystallization
Human MDM2 (residues 18–111 or 1–125) was cloned into the pET26
vector and expressed in the Escherichia coli BL21(DE3) Rosetta strain
(Invitrogen). Cells were grown at 37C and induced with 1 mM isopropyl
b-D-1-thiogalactopyranoside at an OD600 nm of 0.8 and grown for an addi-
tional 4 hr at 37C. The recombinant protein was expressed into inclusion
bodies. The inclusion bodies were isolated by centrifugation of the bacterial
lysate and washed with PBS containing 0.05% Triton X-100, and they were
then subsequently solubilized in 6 M GuHCl in 100 mM Tris-HCl (pH 8.0),
including 1 mM EDTA and 10 mM b-mercaptoethanol. The protein was
then dialyzed against 4 M GuHCl (pH 3.5) and 10 mM b-mercaptoethanol.
For renaturation, the protein was diluted (1:100) into 10 mM Tris-HCl
(pH 7.0), containing 1 mM EDTA and 10 mM b-mercaptoethanol, by adding
the protein in several pulses into the refolding buffer. Refolding was per-
formed overnight at 4C. Ammonium sulfate was then added to the final con-
centration of 1.5 M, and after 3 hr the sample was mixed with 10 ml of the
butyl sepharose 4 Fast Flow (Pharmacia, FRG). The protein was eluted
with 100 mM Tris-HCl (pH 7.2), containing 5 mM b-mercaptoethanol, and
was further purified on the HiLoad 16/60 Superdex200 gel filtration (Pharma-
cia) into the buffer containing 5 mM Tris-HCl (pH 8.0), 50 mM NaCl, and
10 mM b-mercaptoethanol.Structure 21, 2143–2151, December 3, 2013 ªProtein Crystallization
Human MDM2 (residues 18–111) preparations in
5 mM Tris-HCl (pH 8.0), 50 mM NaCl, and
10 mM b-mercaptoethanol were mixed with the
molar excess of the small molecule inhibitors;
the protein complexes were concentrated to
about 20 mg/ml (KK271) or 15 mg/ml (YH300)
and subjected to the crystallization screening
with the sitting drop vapor diffusion method.
The crystals of the MDM2-KK271 complex ap-
peared after several days at 4C in 0.2 M ammo-
nium nitrate and 20% (w/v) PEG 3350, forming
hexagonal bipyramides. The crystals of the
MDM2-YH300 complex appeared after severaldays at 4C in 0.2M dipotassium phosphate and 2.2 M ammonium sulfate,
forming hexagonal bipyramides. All crystals were plunge-frozen in liquid ni-
trogen, with 30% glycerol added to the mother liquor.
Data Collection and Structure Solution
The data sets were collected on the SLS beamline PXII at the Paul Scherrer
Institut. The collected data were indexed, integrated, scaled, and merged
with XDS and XSCALE (Kabsch, 1993). The MDM2-KK271 crystal belonged
to P6522 space group and diffracted to 2.15 A˚, whereas the MDM2-YH300
crystal belonged to P41 space group and diffracted to 2.0 A˚. For KK271-
MDM2 crystals, one complex containing one protein molecule and two inhib-
itor molecules was present in the asymmetric unit; for the YH300-MDM2
crystals, two complexes containing one protein and inhibitor molecules were
present in the asymmetric unit. Phase problem was solved by molecular
replacement using the Molrep program (Vagin and Teplyakov, 1997) from
the CCP4 suite (Bailey, 1994). A MDM2 molecule from MDM2-nutlin cocrystal
structure (1RV1; Czarna et al., 2009) was used as a search model. The model
was then subsequently improved by Arp/Warp (Perrakis et al., 1999) and
manually rebuilt by iterative electron density fitting in MIFit program (http://
code.google.com/p/mifit/) and refinement with Refmac5 (Murshudov et al.,
1997). Ligand molecule and Refmac5 dictionary restraints were created using
the dictionary module in MIFit. Water molecules were added by Arp/Warp sol-
vent module. In a model of KK271-MDM2, the electron densities for residues
18–24 and 109–111 were missing, and thus those residues were not included
in the model. For the YH270-MDM2 model, only residue 111 was invisible in
the electron density. Additionally, several atoms belonging to side chains
atoms without clear electron density were omitted in the model. Data collec-
tion and refinement statistics are summarized in Table 1.
Molecular Dynamics
The molecular dynamics (MD) simulations were performed using the
GROMACS (v. 5.4.3) molecular modeling package (Van Der Spoel et al.,
2005). Starting coordinates of the modeled systems were taken from the
respective refined crystallographic structures of protein-ligand complexes.
When needed, ligand and/or lid residues (N-terminal) coordinates were
removed from the original cocrystallized systems in order to assess its dy-
namics consequences. All systems were simulated using OPLS all-atom force
field (Kaminski et al., 2001) in an explicit water solvent scheme (TIP3 water
molecule model [Jorgensen et al., 1983], with 0.15 NaCl concentration for
charge neutralization) and periodic boundary conditions. The long-range elec-
trostatic interactions were computed using Fast Particle-Mesh Ewald (PME)2013 Elsevier Ltd All rights reserved 2147
Figure 5. Conformational Dynamics of the Tyr100 Side Chain upon
Binding Different Ligands
The Tyr100 side chain is flipping between two metastable ‘‘open’’ and
‘‘closed’’ states. The YH300 molecule is able to stabilize it in ‘‘open’’ confor-
mation.
See also Figures S5 and S6.
Structure
Inhibitors of MDM2-p53(Darden et al., 1993), using a grid spacing of 1.2 A˚. The van der Waals and
short-range electrostatic interactions were computed using a cutoff of 14
and 11 A˚, respectively. The neighbor list was updated every ten steps. The2148 Structure 21, 2143–2151, December 3, 2013 ª2013 Elsevier Ltdapplication LINCS algorithm (Hess et al., 1997) to all atom bonds allowed
the use of 0.002 ps for time step integration.
An equilibration process was applied to all modeled systems before running
the actual production simulation. The equilibration started with two consecu-
tive minimization processes: first, the 2,000 steepest descendant minimization
steps, and second, 200 steps using the conjugate gradient algorithm. Subse-
quently, two short MD simulations (100 ps each) were performed. The first one
ran under constant temperature and volume ensemble at 300 K using a Nose-
Hoover thermostat (t = 0.1 ps) (Nose, 1984; Hoover, 1985), followed by second
simulation in NTP ensemble using Parrinello-Rahman (Parrinello and Rahman,
1981) pressure coupling at 1 bar (t = 0.1 ps). Finally, 5 ns of MD simulation in
NTP ensemble (keeping the conditions from the last equilibration process) was
performed.
Fluorescence Polarization Binding Assays
All fluorescence experiments were performed as described by Czarna et al.
(2009). Briefly, the fluorescence polarization experiments were read on an
Ultra Evolution 384-well plate reader (Tecan) with the 485 nm excitation and
535 nm emission filters. The fluorescence intensities parallel (Intparallel) and
perpendicular (Intperpedicular) to the plane of excitation were measured in black
384-well NBS assay plates (Corning) at room temperature (20C). All fluores-
cence polarization values were expressed in millipolarization units (mP). The
binding affinity of the fluorescent p53-derived peptide of Hu et al. (2007)
toward MDM2 protein was determined in a buffer that contained 50 mM
NaCl, 10 mM Tris (pH 8.0), 1 mM EDTA, and 10% DMSO. Each sample con-
tained 10 nM of the fluorescent P4 peptide and from 0 to 1 mM of MDM2 in a
final volume of 50 ml. Next, the competition binding assays were performed
using the 10 nM fluorescent P4 peptide, 15 nM MDM2 (75% of the peptide
bound), and ligand concentrations ranging from 0 to 100 mM. Plates were
read 30min after mixing all assay components. Binding constant and inhibition
curves were fitted using the SigmaPlot (SPSS Science Software). The experi-
ment results are shown in Table S1.
Isothermal Titration Calorimetry Studies
The isothermal titration calorimetry (ITC) experiments were performed using
a Microcal ITC200 instrument (Microcal). The sample cell of the calorimeter
was loaded with 16 mMMDM2 (1-125) or MDM2 S22P E23G in 50 mM sodium
phosphate (pH 7.5), 150 mMNaCl, and 0.5 mM TCEP. The syringe was loaded
with chemically synthesized p53 peptide (160 and 140 mM for titrations of wild-
type and mutant protein, respectively) in the same buffer. All solutions were
degassed for 10 min. Titrations were performed at 20Cwith injection volumes
of 2 ml and a spacing of 120 s. For the KD determinations, the baseline was
set to zero assuming that the final injections of each titration represent
only the heat of dilution. The data were fit using a one-site binding model avail-
able in the Origin ITC data analysis software (v. 7.0). The results are shown in
Table S2.
NMR Methods
Uniform 15N isotope labeling was achieved by expression of the protein in
M9 minimal media containing 15NH4Cl as nitrogen source. All the spectra
were recorded at 293 K using Bruker DRX600 spectrometer equipped with a
TXI cryoprobe. 1H-15N heteronuclear correlations were obtained using fast
HSQC pulse sequence (Mori et al., 1995). Final step of purification of NMR
samples was gel filtration into NMR buffer containing 50 mM phosphate
(pH 7.2), 150 mM NaCl, and 5 mM DTT. Ten percent (v/v) of D2O was added
to samples to provide lock signal.
Assignment of the amide groups of MDM2 (1-125) was obtained following
Stoll et al. (2001) and Showalter et al. (2008). Thanks to relatively good disper-
sion of MDM2 (1-125), assignment of most of the amide resonances of the
mutant MDM2 (1-125 S22P, E23G) was possible by comparison and manual
inspection of the spectra. Normalized values of chemical shift perturbations
were calculated according to the Pythagoras formula with 15N weighting fac-
tor 0.2.
Antagonist-induced dissociation assays (AIDA) (Bista et al., 2009; D’Silva
et al., 2005) for investigation of potency of small-molecular weight antagonists
to dissociate the MDM2-p53 complex were performed on MDM2(1-125)-
p53(1-312) complex using the SEI-AIDA pulse sequence (Bista et al., 2009).
For calculation of Ki values of the inhibitors (according to Wang, 1995), KD ofAll rights reserved
Figure 6. Chemical Shift Mapping of the N-Terminal ‘‘Lid’’ Helix Interaction Site
(A) Overlay of 1H-15N-HSQC spectra of the WT-MDM2 (1–124) (red) and the ‘‘lid-broken’’ mutant Ser22Glue23-Pro22Gly23 (blue).
(B) Normalized chemical shift perturbations as a function of residue number (calculated according to Stoll et al., 2001).
(C) Alignment of X-ray structures of MDM2 demonstrates that conformation and position of the N-terminal ‘‘lid’’ helix are conserved, regardless of crystallization
conditions or ligand type. Ile19 side chain covering the extended Leu26 pocket is one of the conserved elements of the N-terminal helix (Macchiarulo et al., 2008).
(D) Chemical shift perturbations plotted onto the structure of MDM2 containing the ‘‘lid’’ element; yellow (>0.075 ppm), orange (>0.1 ppm), and red (>0.125). The
‘‘lid’’ helix is depicted asmolecular surface. The site of the mutation is rendered in green. The chemical shifts are concentrated around position of the ‘‘lid’’ seen in
crystal structure of MDM2-YH300, confirming that the ‘‘lid’’ in solution maintains similar orientation and interactions.
See also Table S3.
Structure
Inhibitors of MDM2-p53MDM2-p53 interaction was set to the value obtained in ITC measurements
with p53 (residues 19–37).
AIDA-NMR Experiment
In this competition experiment (Bista et al., 2009), dissociation of MDM2-p53
complex was monitored by 1H NMR spectroscopy and the MDM2-antagonist
inhibition constant was calculated according to Krajewski et al. (2007). Con-
centrations used in the assay include 6.3 mM MDM2-p53 complex and 6.8
6.3 mM inhibitor. Dissociation constants were assumed to be the same as
for the p53 (residues 19–37) peptide used for ITC. Results of the experiment
are shown in Table S3.Table 2. ITCExperiments of Binding p53Peptide to theWild-Type
and Mutated MDM2
Experiment Result
MDM2 (1–125) + p53 (17–37) KD = 375 (±23) nM DH = 7.8 (±0.2)
kcal M1 DS = 2.7 cal M1K1
MDM2 (1–125, S22P E23G) + p53
(17–37)
KD = 112 (±9) nM DH = 11.2 (±0.1)
kcal M1 DS = 6.2 cal M1K1
See also Table S2.
Structure 21, 2143–21Synthesis
The compounds were synthetized by two variants of the Ugi multicomponent
reactions as depicted in Figure 2. For detail of the syntheses, see the Supple-
mental Experimental Procedures.
ACCESSION NUMBERS
The coordinates and structure factors have been deposited in the Protein Data
Bank with the accession numbers 4MDN and 4MDQ.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, three tables, and onemovie and can be foundwith this article online
at http://dx.doi.org/10.1016/j.str.2013.09.006.
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